Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
Liang Huang(Jinan University), Zhimin Shao(Shanghai Medical College of Fudan University), Zefei Jiang, Liheng Zhou(Shanghai Jiao Tong University), Zhongsheng Tong(Institute of Oncology NN Petrov), Hong Zheng(Sichuan University), Xiaojia Wang(Wenzhou Medical University), Jifeng Feng(Zhejiang Cancer Hospital), Shiying Yu(Dalian Ocean University), Lijun Di(University of Macau), Xiangqun Song(Tumor Hospital of Guangxi Medical University), Yunpeng Liu(Shenyang Institute of Automation), Hongyu Zheng(Sichuan University), Yongsheng Wang(Lanzhou University of Technology), Kunwei Shen(Shanghai Jiao Tong University)
Cited by 10
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k